# Radium-223 in Combination With Enzalutamide

> **NCT02225704** · PHASE2 · COMPLETED · sponsor: **Cancer Trials Ireland** · enrollment: 45 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Radium-223 and enzalutamide

## Key facts

- **NCT ID:** NCT02225704
- **Lead sponsor:** Cancer Trials Ireland
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-03
- **Primary completion:** 2017-07
- **Final completion:** 2021-11-23
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02225704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02225704, "Radium-223 in Combination With Enzalutamide". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02225704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*